Rapid diagnosis of sepsis

Virulence

Volumn 5, Issue 1, 2014, Pages 154-160

  Bloos, Frank ^a   Reinhart, Konrad ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Biomarker; Cytokines; Diagnosis; PCR; Procalcitonin; Sepsis

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; C REACTIVE PROTEIN; CD14 ANTIGEN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; PROCALCITONIN; TOLL LIKE RECEPTOR 4; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR; UROKINASE RECEPTOR; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; CALCITONIN; CARRIER PROTEIN; CYTOKINE; IL6 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN; PLAUR PROTEIN, HUMAN; PROTEIN PRECURSOR; TREM1 PROTEIN, HUMAN;

ALGORITHM; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BLOODSTREAM INFECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); MICROORGANISM DETECTION; MULTICENTER STUDY (TOPIC); NONHUMAN; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; SYSTEMATIC REVIEW (TOPIC); BLOOD; DIAGNOSIS; PCR;

BIOMARKER; CYTOKINES; DIAGNOSIS; PCR; PROCALCITONIN; SEPSIS;

ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CARRIER PROTEINS; HUMANS; INTERLEUKIN-6; MEMBRANE GLYCOPROTEINS; POLYMERASE CHAIN REACTION; PROTEIN PRECURSORS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SEPSIS;

EID: 84891695009     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.27393     Document Type: Review

References (98)

1. Levy MM, Artigas A, Phillips GS, Rhodes A, Beale R, Osborn T, Vincent JL, Townsend S, Lemeshow S, Dellinger RP. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis 2012; 12:919-24. PMID:23103175; http://dx.doi. org/10.1016/S1473-3099(12)70239-6
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-54. PMID:12700374; http://dx.doi.org/10.1056/ NEJMoa022139
3. Rohde JM, Odden AJ, Bonham C, Kuhn L, Malani PN, Chen LM, Flanders SA, Iwashyna TJ. The epidemiology of acute organ system dysfunction from severe sepsis outside of the intensive care unit. J Hosp Med 2013; 8:243-7. PMID:23401431; http://dx.doi. org/10.1002/jhm.2012
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10. PMID:11445675; http://dx.doi. org/10.1097/00003246-200107000-00002
5. Bone RC, Fisher CJ Jr., Clemmer TP, Slotman GJ, Metz CA, Balk RA; Methylprednisolone Severe Sepsis Study Group. Sepsis syndrome: a valid clinical entity. Crit Care Med 1989; 17:389-93. PMID:2651003; http://dx.doi. org/10.1097/00003246-198905000-00002
6. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-74. PMID:1597042; http:// dx.doi.org/10.1097/00003246-199206000-00025
7. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al.; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39:165-228. PMID:23361625; http://dx.doi. org/10.1007/s00134-012-2769-8
8. Ferrer R, Artigas A, Levy MM, Blanco J, González- Díaz G, Garnacho-Montero J, Ibáñez J, Palencia E, Quintana M, de la Torre-Prados MV; Edusepsis Study Group. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008; 299:2294-303. PMID:18492971; http://dx.doi.org/10.1001/ jama.299.19.2294
9. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Pérez XL, Sirvent JM; Edusepsis Study Group. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009; 180:861-6. PMID:19696442; http://dx.doi.org/10.1164/ rccm.200812-1912OC
10. MacArthur RD, Miller M, Albertson T, Panacek E, Johnson D, Teoh L, Barchuk W. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004; 38:284-8. PMID:14699463; http:// dx.doi.org/10.1086/379825
11. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273:117-23. PMID:7799491; http://dx.doi.org/10.1001/ jama.1995.03520260039030
12. Vincent JL. Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 1997; 25:372-4. PMID:9034279; http://dx.doi. org/10.1097/00003246-199702000-00029
13. Marshall JC. SIRS and MODS: what is their relevance to the science and practice of intensive care? Shock 2000; 14:586-9. PMID:11131905; http:// dx.doi.org/10.1097/00024382-200014060-00002
14. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-6. PMID:12682500; http://dx.doi. org/10.1097/01.CCM.0000050454.01978.3B
15. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-54. PMID:9971870; http://dx.doi. org/10.1056/NEJM199902113400607
16. van Vugt SF, Broekhuizen BD, Lammens C, Zuithoff NP, de Jong PA, Coenen S, Ieven M, Butler CC, Goossens H, Little P, et al.; GRACE consortium. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ 2013; 346:f2450. PMID:23633005; http://dx.doi. org/10.1136/bmj.f2450
17. Yu CW, Juan LI, Wu MH, Shen CJ, Wu JY, Lee CC. Systematic review and meta-analysis of the diagnostic accuracy of procalcitonin, C-reactive protein and white blood cell count for suspected acute appendicitis. Br J Surg 2013; 100:322-9. PMID:23203918; http:// dx.doi.org/10.1002/bjs.9008
18. Warschkow R, Beutner U, Steffen T, Müller SA, Schmied BM, Güller U, Tarantino I. Safe and early discharge after colorectal surgery due to C-reactive protein: a diagnostic meta-analysis of 1832 patients. Ann Surg 2012; 256:245-50. PMID:22735714; http://dx.doi.org/10.1097/SLA.0b013e31825b60f0
19. Warschkow R, Ukegjini K, Tarantino I, Steffen T, Müller SA, Schmied BM, Marti L. Diagnostic study and meta-analysis of C-reactive protein as a predictor of postoperative inflammatory complications after pancreatic surgery. J Hepatobiliary Pancreat Sci 2012; 19:492-500. PMID:22038499; http://dx.doi. org/10.1007/s00534-011-0462-x
20. Warschkow R, Tarantino I, Ukegjini K, Beutner U, Müller SA, Schmied BM, Steffen T. Diagnostic study and meta-analysis of C-reactive protein as a predictor of postoperative inflammatory complications after gastroesophageal cancer surgery. Langenbecks Arch Surg 2012; 397:727-36. PMID:22398436; http:// dx.doi.org/10.1007/s00423-012-0944-6
21. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39:206-17. PMID:15307030; http://dx.doi.org/10.1086/421997
22. Su L, Han B, Liu C, Liang L, Jiang Z, Deng J, Yan P, Jia Y, Feng D, Xie L. Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. BMC Infect Dis 2012; 12:157. PMID:22809118; http://dx.doi. org/10.1186/1471-2334-12-157
23. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/ systemic antineutrophil cytoplasmic antibodyassociated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997; 40:1250-6. PMID:9214425
24. Meisner M, Tschaikowsky K, Hutzler A, Schick C, Schüttler J. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med 1998; 24:680-4. PMID:9722037; http:// dx.doi.org/10.1007/s001340050644
25. Meisner M, Adina H, Schmidt J. Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit Care 2006; 10:R1. PMID:16356205; http://dx.doi. org/10.1186/cc3910
26. Schmit X, Vincent JL. The time course of blood C-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis. Infection 2008; 36:213-9. PMID:18463788; http://dx.doi.org/10.1007/ s15010-007-7077-9
27. Hoeboer SH, Groeneveld AB. Changes in circulating procalcitonin versus C-reactive protein in predicting evolution of infectious disease in febrile, critically ill patients. PLoS One 2013; 8:e65564. PMID:23762396; http://dx.doi.org/10.1371/ journal.pone.0065564
28. Póvoa P, Teixeira-Pinto AM, Carneiro AH; Portuguese Community-Acquired Sepsis Study Group SACiUCI. C-reactive protein, an early marker of community-acquired sepsis resolution: a multicenter prospective observational study. Crit Care 2011; 15:R169. PMID:21762483; http://dx.doi. org/10.1186/cc10313
29. Tschaikowsky K, Hedwig-Geissing M, Schmidt J, Braun GG. Lipopolysaccharide-binding protein for monitoring of postoperative sepsis: complemental to C-reactive protein or redundant? PLoS One 2011; 6:e23615. PMID:21901123; http://dx.doi. org/10.1371/journal.pone.0023615
30. Tschaikowsky K, Hedwig-Geissing M, Braun GG, Radespiel-Troeger M. Predictive value of procalcitonin, interleukin-6, and C-reactive protein for survival in postoperative patients with severe sepsis. J Crit Care 2011; 26:54-64. PMID:20646905; http://dx.doi.org/10.1016/j.jcrc.2010.04.011
31. Becker K, Müller B, Nylen ES. Calcitonin gene family of peptides. In: Becker K, ed. Principles and practice of endocrinology and metabolism. Philadelphia: J.B. Lippincott Co., 2001:520-34
32. Bloos F, Marshall JC, Dellinger RP, Vincent JL, Gutierrez G, Rivers E, Balk RA, Laterre PF, Angus DC, Reinhart K, et al. Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. Crit Care 2011; 15:R88 http://dx.doi.org/10.1186/cc10087. PMID:21385367
33. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341:515-8. PMID:8094770; http:// dx.doi.org/10.1016/0140-6736(93)90277-N
34. Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med 1998; 24:888-9. PMID:9757936; http://dx.doi. org/10.1007/s001340050683
35. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13:426-35. PMID:23375419; http:// dx.doi.org/10.1016/S1473-3099(12)70323-7
36. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34:1996-2003. PMID:16715031; http:// dx.doi.org/10.1097/01.CCM.0000226413.54364.36
37. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7:210-7. PMID:17317602; http:// dx.doi.org/10.1016/S1473-3099(07)70052-X
38. Reinhart K, Meisner M. Biomarkers in the critically ill patient: procalcitonin. Crit Care Clin 2011; 27:253-63. PMID:21440200; http://dx.doi.org/10.1016/j. ccc.2011.01.002
39. Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, Luyt CE, Chastre J, Tubach F, Kristoffersen KB, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012; 55:651-62. PMID:22573847; http://dx.doi.org/10.1093/cid/ cis464
40. Dou YH, Du JK, Liu HL, Shong XD. The role of procalcitonin in the identification of invasive fungal infection-a systemic review and metaanalysis. Diagn Microbiol Infect Dis 2013; 76:464-9. PMID:23711529; http://dx.doi.org/10.1016/j. diagmicrobio.2013.04.023
41. Karlsson S, Heikkinen M, Pettilä V, Alila S, Väisänen S, Pulkki K, Kolho E, Ruokonen E; Finnsepsis Study Group. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care 2010; 14:R205. PMID:21078153; http://dx.doi.org/10.1186/cc9327
42. Charles PE, Tinel C, Barbar S, Aho S, Prin S, Doise JM, Olsson NO, Blettery B, Quenot JP. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care 2009; 13:R38. PMID:19291325; http://dx.doi.org/10.1186/cc7751
43. Schuetz P, Maurer P, Punjabi V, Desai A, Amin DN, Gluck E. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care 2013; 17:R115. PMID:23787145; http://dx.doi.org/10.1186/cc12787
44. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Müller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600-7. PMID:14987884; http:// dx.doi.org/10.1016/S0140-6736(04)15591-8
45. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174:84-93. PMID:16603606; http://dx.doi.org/10.1164/rccm.200512-1922OC
46. Schuetz P, Müller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; 9:CD007498. PMID:22972110
47. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011; 39:1792-9. PMID:21358400; http://dx.doi.org/10.1097/ CCM.0b013e31821201a5
48. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177:498-505. PMID:18096708; http://dx.doi.org/10.1164/ rccm.200708-1238OC
49. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Løken J, Steensen M, Fox Z, et al.; Procalcitonin And Survival Study (PASS) Group. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011; 39:2048-58. PMID:21572328; http://dx.doi. org/10.1097/CCM.0b013e31821e8791
50. Sponholz C, Sakr Y, Reinhart K, Brunkhorst F. Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature. Crit Care 2006; 10:R145. PMID:17038199; http://dx.doi.org/10.1186/cc5067
51. Schuetz P, Affolter B, Hunziker S, Winterhalder C, Fischer M, Balestra GM, Hunziker P, Marsch S. Serum procalcitonin, C-reactive protein and white blood cell levels following hypothermia after cardiac arrest: a retrospective cohort study. Eur J Clin Invest 2010; 40:376-81. PMID:20192974; http://dx.doi. org/10.1111/j.1365-2362.2010.02259.x
52. Clec'h C, Ferriere F, Karoubi P, Fosse JP, Cupa M, Hoang P, Cohen Y. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med 2004; 32:1166-9. PMID:15190968; http:// dx.doi.org/10.1097/01.CCM.0000126263.00551.06
53. Giovanella L, Verburg FA, Imperiali M, Valabrega S, Trimboli P, Ceriani L. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules. Clin Chem Lab Med 2013; 51:1477-81. PMID:23314540; http://dx.doi.org/10.1515/ cclm-2012-0610
54. Song M, Kellum JA. Interleukin-6. Crit Care Med 2005; 33(Suppl):S463-5. PMID:16340422; http:// dx.doi.org/10.1097/01.CCM.0000186784.62662.A1
55. Billeter A, Turina M, Seifert B, Mica L, Stocker R, Keel M. Early serum procalcitonin, interleukin-6, and 24-hour lactate clearance: useful indicators of septic infections in severely traumatized patients. World J Surg 2009; 33:558-66. PMID:19148699; http://dx.doi.org/10.1007/s00268-008-9896-y
56. Oberhoffer M, Russwurm S, Bredle D, Chatzinicolaou K, Reinhart K. Discriminative power of inflammatory markers for prediction of tumor necrosis factor-alpha and interleukin-6 in ICU patients with systemic inflammatory response syndrome (SIRS) or sepsis at arbitrary time points. Intensive Care Med 2000; 26(Suppl 2):S170-4. PMID:18470714
57. Sakr Y, Burgett U, Nacul FE, Reinhart K, Brunkhorst F. Lipopolysaccharide binding protein in a surgical intensive care unit: a marker of sepsis? Crit Care Med 2008; 36:2014-22. PMID:18552695; http://dx.doi. org/10.1097/CCM.0b013e31817b86e3
58. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J; Geneva Sepsis Network. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164:396-402. PMID:11500339; http://dx.doi.org/10.1164/ajrccm.164.3.2009052
59. Tsalik EL, Jaggers LB, Glickman SW, Langley RJ, van Velkinburgh JC, Park LP, Fowler VG, Cairns CB, Kingsmore SF, Woods CW. Discriminative value of inflammatory biomarkers for suspected sepsis. J Emerg Med 2012; 43:97-106. PMID:22056545; http://dx.doi.org/10.1016/j.jemermed.2011.05.072
60. Uusitalo-Seppälä R, Koskinen P, Leino A, Peuravuori H, Vahlberg T, Rintala EM. Early detection of severe sepsis in the emergency room: diagnostic value of plasma C-reactive protein, procalcitonin, and interleukin-6. Scand J Infect Dis 2011; 43:883-90. PMID:21892899; http://dx.doi.org/10.3109/00365548.2011.600325
61. Rego MA, Martinez FE, Elias J, Mussi-Pinhata MM. Diagnostic value of interleukin-6 and C-reactive protein on early onset bacterial infection in preterm neonates with respiratory distress. J Perinat Med 2010; 38:527-33. PMID:20443669; http://dx.doi. org/10.1515/jpm.2010.071
62. Fioretto JR, Martin JG, Kurokawa CS, Carpi MF, Bonatto RC, Ricchetti SM, de Moraes MA, Padovani CR. Interleukin-6 and procalcitonin in children with sepsis and septic shock. Cytokine 2008; 43:160-4. PMID:18565757; http://dx.doi.org/10.1016/j. cyto.2008.05.005
63. Diepold M, Noellke P, Duffner U, Kontny U, Berner R. Performance of Interleukin-6 and Interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of lowrisk. BMC Infect Dis 2008; 8:28. PMID:18321393; http://dx.doi.org/10.1186/1471-2334-8-28
64. Khassawneh M, Hayajneh WA, Kofahi H, Khader Y, Amarin Z, Daoud A. Diagnostic markers for neonatal sepsis: comparing C-reactive protein, interleukin-6 and immunoglobulin M. Scand J Immunol 2007; 65:171-5. PMID:17257222; http://dx.doi. org/10.1111/j.1365-3083.2006.01878.x
65. Chaudhary N, Kosaraju K, Bhat K, Bairy I, Borker A. Significance of interleukin-6 (IL-6) and C-reactive protein (CRP) in children and young adults with febrile neutropenia during chemotherapy for cancer: a prospective study. J Pediatr Hematol Oncol 2012; 34:617-23. PMID:22983415; http://dx.doi. org/10.1097/MPH.0b013e3182677fc6
66. Miguel-Bayarri V, Casanoves-Laparra EB, Pallás- Beneyto L, Sancho-Chinesta S, Martín-Osorio LF, Tormo-Calandín C, Bautista-Rentero D. Prognostic value of the biomarkers procalcitonin, interleukin-6 and C-reactive protein in severe sepsis. Med Intensiva 2012; 36:556-62. PMID:22495097; http://dx.doi. org/10.1016/j.medin.2012.01.014
67. Pettilä V, Hynninen M, Takkunen O, Kuusela P, Valtonen M. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med 2002; 28:1220-5. PMID:12209268; http://dx.doi.org/10.1007/ s00134-002-1416-1
68. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-8. PMID:8379598; http://dx.doi. org/10.7326/0003-4819-119-8-199310150-00001
69. Shenkin A, Fraser WD, Series J, Winstanley FP, McCartney AC, Burns HJ, Van Damme J. The serum interleukin 6 response to elective surgery. Lymphokine Res 1989; 8:123-7. PMID:2786596
70. Nast-Kolb D, Waydhas C, Gippner-Steppert C, Schneider I, Trupka A, Ruchholtz S, Zettl R, Schweiberer L, Jochum M. Indicators of the posttraumatic inflammatory response correlate with organ failure in patients with multiple injuries. J Trauma 1997; 42:446-54. discussion 454-5. PMID:9095112; http://dx.doi. org/10.1097/00005373-199703000-00012
71. Robak T, Gladalska A, Stepień H, Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm 1998; 7:347-53. PMID:9883970; http://dx.doi. org/10.1080/09629359890875
72. Perez-Villa F, Benito B, Llancaqueo M, Cuppoletti A, Roig E. Elevated levels of serum interleukin-6 are associated with low grade cellular rejection in patients with heart transplantation. Transplant Proc 2006; 38:3012-5. PMID:17112887; http://dx.doi. org/10.1016/j.transproceed.2006.08.113
73. Reinhart K, Bauer M, Riedemann NC, Hartog CS. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev 2012; 25:609-34. PMID:23034322; http://dx.doi.org/10.1128/ CMR.00016-12
74. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001; 410:1103-7. PMID:11323674; http://dx.doi. org/10.1038/35074114
75. Gibot S, Kolopp-Sarda MN, Béné MC, Cravoisy A, Levy B, Faure GC, Bollaert PE. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004; 141:9-15. PMID:15238365; http://dx.doi. org/10.7326/0003-4819-141-1-200407060-00009
76. Jeong SJ, Song YG, Kim CO, Kim HW, Ku NS, Han SH, Choi JY, Kim JM. Measurement of plasma sTREM-1 in patients with severe sepsis receiving early goal-directed therapy and evaluation of its usefulness. Shock 2012; 37:574-8. PMID:22395243; http:// dx.doi.org/10.1097/SHK.0b013e318250da40
77. Jiyong J, Tiancha H, Wei C, Huahao S. Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in bacterial infection: a metaanalysis. Intensive Care Med 2009; 35:587-95. PMID:18936908; http://dx.doi.org/10.1007/ s00134-008-1333-z
78. Wu Y, Wang F, Fan X, Bao R, Bo L, Li J, Deng X. Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis. Crit Care 2012; 16:R229. PMID:23194114; http://dx.doi.org/10.1186/cc11884
79. Ferat-Osorio E, Wong-Baeza I, Esquivel-Callejas N, Figueroa-Figueroa S, Duarte-Rojo A, Guzmán- Valdivia-Gómez G, Rodea-Rosas H, Torres- González R, Sánchez-Fernández P, Arriaga-Pizano L, et al. Triggering receptor expressed on myeloid cells-1 expression on monocytes is associated with inflammation but not with infection in acute pancreatitis. Crit Care 2009; 13:R69. PMID:19442309; http://dx.doi.org/10.1186/cc7876
80. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001; 13:85-94. PMID:11257452; http://dx.doi. org/10.1016/S0898-6568(00)00149-2
81. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-3. PMID:1698311; http:// dx.doi.org/10.1126/science.1698311
82. Prucha M, Herold I, Zazula R, Dubska L, Dostal M, Hildebrand T, Hyanek J. Significance of lipopolysaccharide-binding protein (an acute phase protein) in monitoring critically ill patients. Crit Care 2003; 7:R154-9. PMID:14624690; http://dx.doi. org/10.1186/cc2386
83. Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP, Lemke JH. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999; 180:1584-9. PMID:10515819; http:// dx.doi.org/10.1086/315093
84. Gaïni S, Koldkjaer OG, Pedersen C, Pedersen SS. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in communityacquired infections and sepsis: a prospective study. Crit Care 2006; 10:R53. PMID:16569262; http:// dx.doi.org/10.1186/cc4866
85. Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009; 27:157-72. PMID:19893210; http://dx.doi. org/10.1155/2009/504294
86. Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, Schultz MJ. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 2012; 38:1418-28. PMID:22706919; http://dx.doi.org/10.1007/ s00134-012-2613-1
87. Jalkanen V, Yang R, Linko R, Huhtala H, Okkonen M, Varpula T, Pettilä V, Tenhunen J; FINNALI Study Group. SuPAR and PAI-1 in critically ill, mechanically ventilated patients. Intensive Care Med 2013; 39:489-96. PMID:23100007; http://dx.doi. org/10.1007/s00134-012-2730-x
88. Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, Savva A, Tsangaris I, Dimopoulou I, Mouktaroudi M, Raftogiannis M, Georgitsi M, Linnér A, et al. Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care 2012; 16:R149. PMID:22873681; http:// dx.doi.org/10.1186/cc11463
89. Calandra T, Cohen J; International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005; 33:1538-48. PMID:16003060; http://dx.doi.org/10.1097/01. CCM.0000168253.91200.83
90. Pletz MW, Wellinghausen N, Welte T. Will polymerase chain reaction (PCR)-based diagnostics improve outcome in septic patients? A clinical view. Intensive Care Med 2011; 37:1069-76. PMID:21573947; http://dx.doi.org/10.1007/ s00134-011-2245-x
91. Chang SS, Hsieh WH, Liu TS, Lee SH, Wang CH, Chou HC, Yeo YH, Tseng CP, Lee CC. Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis - a systemic review and meta-analysis. PLoS One 2013; 8:e62323. PMID:23734173; http://dx.doi.org/10.1371/journal. pone.0062323
92. Bloos F, Hinder F, Becker K, Sachse S, Mekontso Dessap A, Straube E, Cattoir V, Brun-Buisson C, Reinhart K, Peters G, et al. A multicenter trial to compare blood culture with polymerase chain reaction in severe human sepsis. Intensive Care Med 2010; 36:241-7. PMID:19924398; http://dx.doi. org/10.1007/s00134-009-1705-z
93. Bloos F, Sachse S, Kortgen A, Pletz MW, Lehmann M, Straube E, Riedemann NC, Reinhart K, Bauer M. Evaluation of a polymerase chain reaction assay for pathogen detection in septic patients under routine condition: an observational study. PLoS One 2012; 7:e46003. PMID:23029360; http://dx.doi. org/10.1371/journal.pone.0046003
94. Lehmann LE, Herpichboehm B, Kost GJ, Kollef MH, Stüber F. Cost and mortality prediction using polymerase chain reaction pathogen detection in sepsis: evidence from three observational trials. Crit Care 2010; 14:R186. PMID:20950442; http:// dx.doi.org/10.1186/cc9294
95. Bloos F, Bayer O, Sachse S, Straube E, Reinhart K, Kortgen A. Attributable costs of patients with candidemia and potential implications of polymerase chain reaction-based pathogen detection on antifungal therapy in patients with sepsis. J Crit Care 2013; 28:2-8. PMID:22999484; http://dx.doi. org/10.1016/j.jcrc.2012.07.011
96. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol 2011; 49:665-70. PMID:21106797; http://dx.doi.org/10.1128/JCM.01602-10
97. Hebart H, Klingspor L, Klingebiel T, Loeffler J, Tollemar J, Ljungman P, Wandt H, Schaefer-Eckart K, Dornbusch HJ, Meisner C, et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant 2009; 43:553-61. PMID:19079316; http://dx.doi. org/10.1038/bmt.2008.355
98. Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011; 15:R63. PMID:21324198; http:// dx.doi.org/10.1186/cc10037